Navigation Links
ConvaTec Healthcare Announces Plans to Refinance Secured Term Loans
Date:3/3/2011

SKILLMAN, N.J., March 3, 2011 /PRNewswire/ -- ConvaTec Healthcare, a world-leading developer, manufacturer and marketer of innovative medical technologies for community and hospital care, today announced that, recognizing favorable conditions in the credit markets, it is exploring the option to refinance all or a portion of its senior secured term loans originally entered into on December 22, 2010.

While the year-end audit process is ongoing, ConvaTec presently expects adjusted EBITDA for the year ended December 31, 2010 to be within a range of approximately $425-435mm, although this view is based on a number of assumptions and estimates. ConvaTec management cautions that the foregoing information has not been audited or reviewed by the company's independent auditors and should not be regarded as a representation or forecast by ConvaTec or any other person affiliated with the company regarding the results that will be reported for the year ended December 31, 2010.

About ConvaTecConvaTec is a leading developer and marketer of innovative medical technologies. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. From its operational headquarters in Skillman, New Jersey, the company conducts business in over 100 countries, serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements are all statements other than statements of historical facts.  Certain of these forward looking statements are identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should," or "will" or the negative of such terms or other comparable terminology.  Others can be identified from the context in which the statements are made.  These statements involve a number of risks and uncertainties.  Any forward-looking statements that we make herein and in future reports and statements are not guarantees of future performance, and actual results may differ materially from those in such forward-looking statements as a result of various factors relating to our strategy, outlook and growth prospects, including our operational and financial targets; the expected growth of the markets in which we operate; the competitive environment in which we operate; the economic outlook in general and, in particular, economic conditions in the European and U.S. markets; growth in demand for our products, increases in the penetration of our products into their respective markets, reimbursement rates for our products, or similar measures; and our expansion plans, including planned expansion into and growth in emerging markets; our ability to gain necessary regulatory approvals and desirable reimbursement rates for our newly developed products and technologies; and our ability to market and launch attractive new product designs and technologies.  All forward-looking statements made in this press release are made as of the date hereof, and the risk that actual results will differ materially from expectations expressed herein will increase with the passage of time.  The Company undertakes no duty to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

This announcement is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) (a) to (d)  of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This document is an advertisement for purposes of applicable measures implementing Directive 2003/71/EC.

This announcement is not an offer to sell or the solicitation of an offer to buy the new notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful.Media ContactNimisha Savani908-904-2522Nimisha.savani@convatec.com
'/>"/>

SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ConvaTec Announces New Appointment to Leadership Team
2. ConvaTec Announces New Appointments to Leadership Team
3. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
4. Bradford Barton Named President, ConvaTec U.S.
5. ConvaTec to Present at AdvaMed 2010: The MedTech Conference
6. ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing
7. New Data Supports ConvaTec Negative Pressure Wound Therapy
8. Zimmer Holdings to Present at Barclays Capital 2011 Global Healthcare Conference
9. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
10. Berg Biosystems and GNS Healthcare Announce Joint Venture - MAP Biosystems
11. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):